In recent years, a better understanding of how cancer can adapt to treatment and become insensitive has suggested that, instead of waiting for tumor relapse, therapies could be designed to anticipate and delay the onset of resistance, thus prolonging EGFR-TKI response. The gene discussed is EGFR; the disease is cancer.